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Background
The viral reverse transcriptase (RT) is a major target in the
therapeutic strategy against the human immunodeficiency
virus (HIV). This multifunctional enzyme performs the
viral genome replication by two associated functions:
DNA polymerase and ribonuclease H (RNase H). Both
activities are essential for viral replication and validated
targets. Currently, none of the approved antiviral drugs
acts on both activities, although few classes of compounds
have been reported to inhibit both RT functions in vitro
[1]. In a previous virtual screening [2] we identified a new
isatine-based scaffold for dual functions RT inhibitors that
was further derivatized.
Materials and methods
We performed blind docking studies on wild type HIV-1
RT with the isatine-derivative RMNC6. We employed the
QM-polarized ligand docking protocol utilizing Glide
version 4.5, qsite version 4.5, jaguar 7.0 and maestro 8.5
(Schrodinger Inc, Portland, USA). Residues hypothesized
to be critical for compound binding were mutated by site-
directed mutagenesis. Mutants RTs were tested for
susceptibility to RMNC6 on both RNase H and RNA
dependent DNA polymerase activities.
Results
The isatine-derivative RMNC6 inhibited the RT-associated
RNase H and DNA polymerase activities with IC50 values
of 1.4 and 9.8 µM concentration, respectively. Blind
docking analysis suggested that RMNC6 could bind to
two different RT pockets: the first one close to the
RNase H active site, the second one near to the poly-
merase active site. Conserved residues close to the pri-
mer grip regions were individuated as potentially
critical for inhibitor binding and mutated. Mutagenesis
results identified few amino acid residues in the RNase
H domain that are essential for RNase H inhibition by
RMNC6 but do not influence its DNA polymerase
inhibition. By contrast, mutation of some amino acid
residues in the DNA polymerase domain affects up to
5 fold the inhibition of both DNA polymerase and
RNase H by RMNC6.
Conclusions
The new isatine-derivative RMNC6 was shown to inhibit
both RT functions in the low micromolar range. Mole-
cular modeling and site-directed mutagenesis studies
supported the hypothesis that RMNC6 could bind to
two different RT sites. Binding to the RNase H site
appears to be responsible for RNase H inhibition, while
binding to the DNA polymerase site seems to affect
both RT-associated functions by both short- and long-
range effects.
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